<DOC>
	<DOCNO>NCT01865084</DOCNO>
	<brief_summary>The main purpose study determine tadalafil slow decline walk ability boy Duchenne muscular dystrophy ( DMD ) . The study also assess safety tadalafil side effect might associate boy DMD . Participants receive study treatment ( tadalafil placebo ) first 48 week study , continue open label extension ( OLE ) consist two period participant receive tadalafil . In OLE period 1 , participant receive tadalafil 48 week . Participants complete OLE period 1 continue OLE period 2 receive tadalafil least another 48 week .</brief_summary>
	<brief_title>A Study Tadalafil Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Ambulant male Duchenne muscular dystrophy ( DMD ) confirm typical clinical presentation ( onset clinical sign symptoms 6 year age support elevated serum creatinine kinase level , ongoing difficulty walk ) together either record genetic confirmation DMD diagnosis , record muscle biopsy show nearcomplete dystrophin deficiency ( exclude revertant fiber ) Receiving systemic corticosteroid minimum 6 month immediately prior screening , significant change total daily dosage dose regimen ( except adjust weight change ) minimum 3 month immediately prior screen reasonable expectation total daily dosage dose regimen change significantly ( except adjustment weight ) duration study Able complete six minute walk distance ( 6MWD ) test result within 20 % minimum 2 prerandomization assessment Left ventricular ejection fraction ( LVEF ) â‰¥50 % determined echocardiogram Written inform consent parents/legal guardian obtain prior study procedure perform . In addition , child may require give documented assent , capable . Symptomatic cardiomyopathy heart failure Change prophylactic treatment heart failure within 3 month prior start study treatment Cardiac rhythm disorder History participation gene cellbased therapy , antisense oligonucleotide stop codon readthrough therapy Unable take orally administer tablet Use pharmacologic treatment , corticosteroid , might effect muscle strength within 3 month prior start study treatment ( example , growth hormone , anabolic steroid include testosterone ) New change treatment herbal dietary supplement take expectation effect muscle strength function 1 month prior first dose study drug Surgery might effect muscle strength function within 3 month study entry plan surgery time study Evidence low limb injury may affect performance 6MWD Severe behavioral problem , include severe autism attention deficit disorder , may interfere completion 6MWD Any contraindication tadalafil ( use form organic nitrate , either regularly and/or intermittently , know serious hypersensitivity tadalafil ) History significant renal insufficiency clinical evidence cirrhosis Have know allergy excipients tadalafil tablet , notably lactose Current Phosphodiesterase Type 5 ( PDE5 ) inhibitor therapy treatment within past 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>